← Eichor
Condition: Castration Sensitive Prostate Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Castration Sensitive Prostate Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT05919329PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer,
Phase 2 · 6 location(s) · Northwestern University · NCT06244004A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 · 50 location(s) · Astellas Pharma Global Development, Inc. · NCT07005154Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07290270Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic
Phase 3 · 26 location(s) · Nick Beije · NCT07260435Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati
Phase 2 · 3 location(s) · Mayo Clinic · NCT06378866This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · 341 location(s) · Pfizer · NCT07028853Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06305598Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Phase 2 · 12 location(s) · Fundacion Oncosur · NCT06582628A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01AD
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04633252A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Phase 1 · 1 location(s) · Astellas Pharma Global Development, Inc. · NCT07339267ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Phase 3 · 32 location(s) · Karolinska Institutet · NCT03903835A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 1 · 15 location(s) · Janssen Research & Development, LLC · NCT05818683An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Phase N/A · 1 location(s) · Bayer · NCT06334120Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · 395 location(s) · Canadian Cancer Trials Group · NCT06592924A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
NA · 2 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT05209243A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Phase 1 · 25 location(s) · Astellas Pharma Global Development, Inc. · NCT04729114Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Phase 1 · 12 location(s) · Vir Biotechnology, Inc. · NCT05997615Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed Aft
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06529549Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/I
Phase 1/Phase 2 · 3 location(s) · AdvanCell Pty Limited · NCT05720130Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · 195 location(s) · Alliance for Clinical Trials in Oncology · NCT06931340Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate C
Phase N/A · 4 location(s) · University of Washington · NCT04489719Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-rec
Phase 2 · 3 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06654336A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Trea
Phase 3 · 2 location(s) · ORIC Pharmaceuticals · NCT07723248A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sens
Phase 1 · 1 location(s) · University of Arkansas · NCT06044025PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06652607PROCARE - PROstate Cancer Real World Evidence Registry
Phase N/A · 53 location(s) · UroTrials Company (GmbH) · NCT06835218
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.